E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia
Pramod Pinnamaneni,Jeffrey L. Jorgensen,Hagop M. Kantarjian,Elias Jabbour,Sherry Pierce,Mark Brandt,Sa A. Wang,Sergej Konoplev,Marina Konopleva,Steven M. Kornblau,Tapan M. Kadia,Courtney D. DiNardo,Naveen Pemmaraju,Michael Andreeff,Zeev Estrov,Guillermo Garcia-Manero,Jorge E. Cortes,Farhad Ravandi +17 more
TL;DR: Achieving MRD negative status by MFC at 30 and 90 days post CR is associated with an improved outcome in patients with AML Disclosures No relevant conflicts of interest to declare.
Journal ArticleDOI
Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center
Alfonso Quintás-Cardama,Hagop M. Kantarjian,Susan O'Brien,Elias Jabbour,Guillermo Garcia-Manero,Charles Koller,Sherry Pierce,Moshe Talpaz,Jorge E. Cortes +8 more
TL;DR: While currently superseded by imatinib and other TKIs, IFN-α remains an active agent in CML, capable of inducing inducement of cytogenetic response in 5% and 5% of patients in CCyR, complete molecular response (CMR), major molecular response(MMR), overall survival (OS), transformation-free survival (TFS), and CML cure.
Journal ArticleDOI
A patient-reported outcome measure for symptoms of AML/MDS.
Loretta A. Williams,Araceli Garcia-Gonzalez,Hycienth Ahaneku,Jorge E. Cortes,Guillermo Garcia-Manero,Hagop M. Kantarjian,Qiuling Shi,Gautam Borthakur,Jan A. Burger,Elias Jabbour,Koichi Takahashi,H. Lin,Achala Limaye,Charles S. Cleeland +13 more
TL;DR: The aim is to develop a short, valid, reliable patient-reported outcome measure of AML and MDS symptoms for research and practice.
Journal ArticleDOI
Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.
Fabio P.S. Santos,Ellen J. Schlette,Hagop M. Kantarjian,Rachel L. Sargent,Guillermo Garcia-Manero,Srdan Verstovsek,Tapan M. Kadia,Elias Jabbour,Sherry Pierce,Gautam Borthakur +9 more
TL;DR: Clinical features and survival outcomes of patients with a diagnosis of MDS with myelofibrosis treated at the M.D. Anderson Cancer Center are described, finding that MDS patients who present with fibrotic features in the bone marrow constitute a group with worse survival.
Journal ArticleDOI
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia
Sangeetha Venugopal,Courtney D. DiNardo,Sanam Loghavi,Wei Qiao,Farhad Ravandi,Marina Konopleva,Tapan M. Kadia,Kapil N. Bhalla,Elias Jabbour,Ghayas C Issa,W. Macaron,Naval Daver,Gautam Borthakur,Guillermo Montalban-Bravo,Musa Yilmaz,Keyur Patel,Rashmi Kanagal-Shamanna,Kelly S. Chien,Abhishek Maiti,Hagop M. Kantarjian,Nicholas J. Short +20 more
TL;DR: The prognostic impact of mRUNX1 AML may be treatment-dependent, and the presence of RUNX1 mutations may not impact clinical outcomes when venetoclax-based regimens are used.